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ABSTRACT
Huntington's disease (HD) is a rare, autosomal dominant, progressive neurodegenerative disorder. HD manifests with a
triad of progressive motor, cognitive, and psychiatric symptoms. Our patient was a 39-years-old married female with
over a nine-year history of psychotic symptoms. The patient was diagnosed and treated for schizophrenia. Over the last
2-3 years, the patient had a progressive decline in her Activities of Daily Living, instrumental activities of daily living, and
psychotic symptoms. She developed slurred speech, gait disturbances, frequent falls, involuntary movements of the
trunk and distal extremities, bowel and bladder incontinence, and severe weight loss. Her genetic test for Huntington’s
gene confirmed the diagnosis of HD. She was prescribed Olanzapine, fluoxetine, and clonazepam. Psychotic symptoms
are rare in HD and usually appear well after the motor and cognitive symptoms. Our case highlights an unusual clinical
presentation of HD, which can be diagnostically challenging and lead to diagnostic delays.
KEY WORDS: Huntington’s Disease, Neurodegenerative disorder, psychosis

INTRODUCTION
Huntington's disease (HD) is a rare and slowly
progressing autosomal-dominant neurodegenerative
disorder. The global prevalence of HD is 2.71 per
100,000. The prevalence ranges from 0.4 to 5.70 per
100,000 between Asia to Europe, North America, and
Australia.1,2 HD manifests with progressive cognitive,
motor and psychiatric symptoms. Disease progression
can be variable in individuals; 33-76% of HD patients
can have psychiatric symptoms.3 The most common
psychiatric manifestations in HD include irritability
(60%), aggression (40-60%), apathy (57%),
depression (30%), anxiety (28%), and psychosis
(4-12%).3,4
Psychotic
symptoms
mimicking
schizophrenia are rare in HD. Usually, these symptoms
manifest well after the motor and cognitive
symptoms.5,6 We are sharing here an unusual and
challenging presentation of HD. In our case, the
psychotic symptoms preceded the motor and cognitive
symptoms of HD.

restlessness, verbal anger along with physical outbursts
of aggression, and decline in social participation. The
patient was initially diagnosed as Schizophrenia. She
received multiple antipsychotics and electroconvulsive
therapies (ECTs) during her course of illness. In
response to treatment, the patient had partial
remission in symptoms.
In the past 3 years, the patient progressively declined in
her Activities of Daily Living (ADLs) and was worsening
in psychotic symptoms. She required assistance and
supervision for eating, toileting, and personal care. She
was unable to perform any of her prior social and
occupational responsibilities, for example, domestic
chores and managing the house hold. She developed
slurred speech, decreased vocabulary with answers
limited to few words, gait changes leading to falls and
injuries, dance like movements in distal extremities
progressing further to trunk. Patient also became stool
and urine incontinent and had cachexia.Two of
patient’s family members had history of similar
symptoms and died in their early 40s. Their cause of
death was never established.

CASE PRESENTATION
Our patient was a 39-years-old female, married with
three children. She presented to the psychiatry
outpatient department along with her spouse. The
patient presented with a nine-year history of sleep
decline,
paranoid
feelings,
self-mumbling,
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On mental state examination (MSE), the patient was
restless and agitated, self-mumbling incoherently,
appeared fearful and attempted to hit and bite people
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near her. There was no verbal response to queries. The
patient did not follow any commands. On examination
the patient was hemodynamically stable and her
personal hygiene was poor.Neurological examination was
limited (due to non-cooperation). There was loss of
muscle bulk,
broad-based gait with choreiform
movements.
For assessment and management of the above
symptoms, inpatient psychiatry admission was given. For
the evaluation of the neurological symptoms, we called a
neurology consult. Her lab investigations showed
presence of ASMA antibodies (Table 1), MRI brain
showed involutional changes typical of HD (Table 2 and
Figure 1), and Huntington gene was positive which
confirmed her diagnosis of HD. (Table 3)
The patient was managed on Olanzapine 20mg orally at
night for psychotic and motor symptoms, fluoxetine
20mg orally in the morning for aggression and agitation,
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and clonazepam 2mg/day orally in divided doses for
sleep and motor symptoms. The neurology team did not
add any further treatment. After dietician input, we
started her on high calorie, protein-rich diet. The patient’
agitation improved and her self-mumbling stopped. The
family received details regarding the management and
prognosis of HD with genetic counseling. Due to
financial constraints, the family decided to provide her
with informal nursing care at home after discharge.
At four and eight-week follow-up, the patient was less
irritable, relaxed, and showed no signs of aggression.
She responded to her name and followed commands
partially, including shaking hands and making eye
contact. Her choreiform movements also decreased.
Like before, She required assistance in ADLs but showed
interest in self-care (including bathing, toileting, and
eating).
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Figure 1: MRI brain showing atrophy of bilateral putamen. Globus pallidus is not visualized.
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DISCUSSION
HD is anautosomal-dominant disease, that usually
presents with characteristic clincal manifestation.
However, HD can present and evolve in an atypical
manner during early to middle stage of HD. Therefore,
HD can have a diverse range of initial symptoms.3 In
parkinsonism-predominant phenotype of HD, more
neuropsychiatric manfiestation and cognitive decline is
noted than in chorea-predominant phenotype hence, a
thorough physical examination and approach to history
can help lead to the diagnosis of HD. Psychosis in HD is
rare but reported in multiple case reports. In a study 11%
of the patients had psychosis, out of whom psychotic
symptoms started before the characteristic clinical
symptoms of HD in a majority (55.3%) of the patients.7
Other studies point that psychosis is usually seen well
after characteristic motor and cognitive symptoms of HD
is apparent.8

for improving the patient’s quality of life in HD.9 Lack of
existing data of a rare condition like HD, with an unusual
presentation, can undermine the possibility of
neurodegenerative disorders. An in-depth approach to
case presentation, history and physical examination can
help revising the diagnosis with such challenging
presentations.
At present, there is a lack of treatment guidelines for
psychiatric symptoms in HD. There is supportive
evidence for the use of antidepressants, antipsychotics,
and clonazepam for choreiform movements.
For
agitation
and
irritability,
evidence
suggests
antipsychotics and antidepressant use.4, 10-12 There are
also case reports on using various antipsychotics for the
psychotic symptoms in HD.13-18 A case report from India
supported the use of clozapine and tetrabenazine with
benzodiazepines after lack of response on two
antipsychotics.19

Our case discussed psychotic symptoms prior to onset of
motor and cognitive features (pre-choreic stage). The
existing evidence of pre-choreic psychosis is scarce and
limited to case series and case reports. A case series
mentions three family members who developed severe
psychotic disorder between age 20-40 years, preceding
chorea by three to nine years.6 Another case of a
55-years old male with eight years history of psychosis
progressing to HD is also reported.5

Interestingly, our patient responded well to treatment
better than before. There can be a few reasons for this.
Firstly, there is a possibility of non-compliance due to
lack of insight and possible forgetfulness due to the
cognitive decline of the patient. Secondly, the patient
received fluoxetine and clonazepam besides Olanzapine.
We hypothesize that the drug regimen in combination
improved the motor and psychiatric symptoms
altogether. However, these outcomes are not
generalizable as treatment guidelines based on this case
report only. Our case builds to the current evidence on
atypical HD cases and its management.Combining future
researches to existing literature can help strengthen
ways to adequate symptomatic management.

Our patient had psychotic symptoms for 6-years before
other HD symptoms evolved. Patients with pre-choreic
psychosis on antipsychotic treatment may develop
tardive dyskinesia (TD). The occurrence of TD with motor
symptoms of HD can make a diagnosis of HD difficult.4
The same may have happened with our patient as her
symptoms evolved.

CONCLUSION
Psychotic symptoms are rare in HD and usually appear
well after the motor and cognitive symptoms, unlike this
case. Our case highlights an unusual clinical
presentation of HD, which can be diagnostically
challenging and lead to diagnostic delays.

Our patient had an atypical clinical presentation of HD.
The atypical presentation was diagnostically challenging
and lead to diagnostic delays. Untreated psychiatric
symptoms of HD can be distressing to the patient as well
as the caregiver. Treating psychiatric symptoms is vital
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